Varicose Veins Treatment Market Report 2026

The varicose veins treatment market size has grown strongly in recent years. It will grow from $2.11 billion in 2025 to $2.25 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing prevalence of venous disorders, rising awareness of vascular health, expansion of specialized vein clinics, improved availability of ablation technologies, growing demand for cosmetic procedures.

The varicose veins treatment market size is expected to see strong growth in the next few years. It will grow to $2.85 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing aging population, rising adoption of non-surgical treatments, growing investments in vascular care infrastructure, expansion of ambulatory surgical centers, increasing focus on early diagnosis and intervention. Major trends in the forecast period include increasing adoption of minimally invasive treatment procedures, rising demand for laser-based ablation techniques, growing preference for outpatient treatment settings, expansion of cosmetic vein treatment solutions, enhanced focus on patient recovery and comfort.

The rising demand for minimally invasive procedures is anticipated to drive the expansion of the varicose veins treatment market in the coming years. Minimally invasive procedures involve surgical methods that use small incisions and specialized tools to carry out treatments with reduced tissue trauma, leading to less pain, faster recovery periods, and minimal scarring when compared with conventional open surgeries. The growing preference for minimally invasive techniques is influenced by factors such as shorter recovery times, better clinical outcomes, and an expanding aging population, all of which contribute to improved patient safety, satisfaction, and overall healthcare efficiency. Minimally invasive treatments for varicose veins, including endovenous laser therapy (EVLT) and sclerotherapy, offer effective management of the condition with minimal discomfort, quicker healing, and a lower risk of complications. For instance, in June 2024, the American Society of Plastic Surgeons, a US-based nonprofit professional organization, reported that nearly 25.4 million cosmetic minimally invasive procedures were carried out in 2023, reflecting a 7% increase compared with the previous year. Therefore, the growing demand for minimally invasive procedures is supporting the growth of the varicose veins treatment market.

Major companies operating in the varicose veins treatment market are concentrating on the development of innovative approaches, such as anesthesia-free treatments, to improve patient outcomes, simplify treatment monitoring, expand access to care, and deliver more personalized therapeutic solutions. Anesthesia-free treatment refers to performing medical procedures without the use of anesthesia, which enhances safety, enables faster recovery, and increases patient comfort. For instance, in April 2024, VVT MEDICAL Ltd., an Israel-based medical device manufacturer, received approval from South Korea’s Ministry of Food and Drug Safety for its ScleroSafe platform, an advanced solution designed for minimally invasive varicose vein treatment. The platform employs a nonthermal, nontumescent (NT-NT) technique that removes the need for heat or tumescent anesthesia, ensuring a painless, anesthesia-free procedure. Developed for both medical and aesthetic applications, it emphasizes patient comfort and treatment effectiveness. The ScleroSafe platform has obtained multiple regulatory clearances, including CE Mark certification and FDA 510(k) approval, and adheres to Good Manufacturing Practices (GMP), positioning it as a significant innovation in varicose vein treatment.

In January 2024, VVT MEDICAL Ltd., an Israel-based medical device company, entered into a partnership with Methapharm Inc. to support the treatment of varicose veins using a dual syringe technique. This partnership enables VVT MEDICAL to enhance its footprint in the United States by utilizing Methapharm’s expertise in the promotion and distribution of the ScleroSafe platform for varicose vein therapy. Methapharm Inc. is a Canada-based pharmaceutical company specializing in treatments for varicose veins.

Major companies operating in the varicose veins treatment market are Medtronic PLC, Becton Dickinson and Company, Boston Scientific Corporation, BTG Limited, Merit Medical Systems Incorporated, AngioDynamics Incorporated, Medi USA Limited Partnership, Dornier MedTech GmbH, Sciton Incorporated, Invera Medical Limited, Biolitec AG, Alma Lasers Limited, Won Tech Company Limited, F Care Systems S.A., Vascular Solutions Incorporated, Theraclion S.A., Lumenis Ltd, Syneron Medical Ltd, Quanta System S.p.A, Energist Group, LSO Medical.

North America was the largest region in the varicose veins treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the varicose veins treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the varicose veins treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the varicose veins treatment market by increasing costs of imported laser fibers, radiofrequency catheters, imaging components, and specialized medical devices used in ablation procedures. Hospitals and specialized clinics in North America and Europe are most affected due to reliance on imported treatment equipment, while Asia-Pacific faces higher costs for advanced medical device imports. These tariffs are increasing procedure costs and impacting capital investment decisions. At the same time, they are encouraging domestic manufacturing of vascular treatment devices, regional supplier development, and localized innovation in cost-effective treatment technologies.

The varicose veins treatment market research report is one of a series of new reports that provides varicose veins treatment market statistics, including varicose veins treatment industry global market size, regional shares, competitors with a varicose veins treatment market share, detailed varicose veins treatment market segments, market trends and opportunities, and any further data you may need to thrive in the varicose veins treatment industry. This varicose veins treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Varicose vein treatment includes medical procedures and interventions aimed at relieving symptoms, improving blood flow, and preventing complications caused by enlarged, twisted veins, most commonly in the legs. These treatments also address aesthetic concerns by improving the appearance of affected veins while lowering the risk of related problems such as pain, ulcers, or blood clots.

The primary products used in varicose vein treatment include ablation devices, radiofrequency ablation devices, and laser ablation devices. Ablation devices are medical instruments designed to eliminate or destroy abnormal tissue, such as varicose veins or tumors, using techniques involving heat, cold, or electrical energy. The procedures involved include injection sclerotherapy, endovenous ablation, and surgical ligation or stripping. End users of these treatments include hospitals, specialty clinics, ambulatory surgical centers, and other healthcare facilities.

The varicose veins treatment market consists of revenues earned by entities providing services such as diagnostic services, minimally invasive treatments, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The varicose veins treatment market also includes sales of laser treatment devices, sclerotherapy agents, and radiofrequency ablation devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.